Title: An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese

NCT Number: NCT03085836

SAP Approve Date: 30 August 2017

Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information or company confidential information.

This may include, but is not limited to, redaction of the following:

- Named persons or organizations associated with the study.
- Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder.
- Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study.
STATISTICAL ANALYSIS PLAN

STUDY NUMBER: TAK-438_114

An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects

PHASE 1

Version: Final 2
Date: 30 August 2017

Prepared by:
PPD

Based on:
Protocol Version: Amendment 02
Protocol Date: 21 December 2016

CONFIDENTIAL PROPERTY OF TAKEDA

This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by the recipient that no information contained herein will be published or disclosed without written authorization from Takeda.
1.1 Approval Signatures

Electronic signatures can be found on the last page of this document.

**Study Title:** An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese

**Approvals:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Date</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPD</td>
<td>PPD</td>
<td>PPD</td>
</tr>
<tr>
<td></td>
<td>PPD</td>
<td>Date</td>
</tr>
<tr>
<td></td>
<td>Date</td>
<td>Date</td>
</tr>
<tr>
<td></td>
<td>Date</td>
<td>Date</td>
</tr>
</tbody>
</table>
## 2.0 TABLE OF CONTENTS

1.1 Approval Signatures .................................................................................................. 2

2.0 TABLE OF CONTENTS.................................................................................................3

List of In-Text Tables............................................................................................................ 4
List of In-Text Figures........................................................................................................... 4

3.0 LIST OF ABBREVIATIONS.......................................................................................... 5

4.0 OBJECTIVES................................................................................................................. 7

4.1 Primary Objectives .................................................................................................... 7
4.2 Secondary Objectives ................................................................................................. 7
4.3 Additional Objectives ................................................................................................ 7
4.4 Study Design ............................................................................................................. 7

5.0 ANALYSIS ENDPOINTS............................................................................................... 9

5.1 Primary Endpoints ..................................................................................................... 9
5.2 Additional Endpoints ................................................................................................. 10

6.0 DETERMINATION OF SAMPLE SIZE ..................................................................... 11

7.0 METHODS OF ANALYSIS AND PRESENTATION................................................... 12

7.1 General Principles.................................................................................................... 12
7.1.1 Study Definitions ............................................................................................... 12
7.1.2 Definition of Study Days.................................................................................... 12
7.1.3 Definition of Study Visit Windows .................................................................... 12
7.1.4 Method of Data Conversion and Handling of Missing Data............................... 13

7.2 Analysis Sets ........................................................................................................... 14

7.3 Disposition of Subjects ............................................................................................ 14
7.3.1 Study Information .............................................................................................. 14
7.3.2 Screen Failures ................................................................................................... 14
7.3.3 Subject Eligibility .............................................................................................. 15
7.3.4 Disposition of Subjects ...................................................................................... 15
7.3.5 Protocol Deviations and Analysis Sets ............................................................... 16

7.4 Demographic and Other Baseline Characteristics..................................................... 17

7.5 Medical History and Concurrent Medical Conditions.............................................. 17

7.6 Medication History and Concomitant Medications.................................................. 17

7.7 Efficacy Analysis...................................................................................................... 18

7.8 Pharmacokinetic/Pharmacodynamic Analysis ......................................................... 18
7.8.1 Pharmacokinetic Analysis .................................................................................. 18
7.8.2 Pharmacodynamic Analysis .............................................................................. 19
7.9 Other Outcomes

7.10 Safety Analysis

7.10.1 Adverse Events

7.10.2 Clinical Laboratory Evaluations

7.10.3 Vital Signs

7.10.4 12-Lead ECGs

7.10.5 Other Observations Related to Safety

7.11 Interim Analysis

7.12 Changes in the Statistical Analysis Plan

8.0 REFERENCES

9.0 APPENDIX

9.1 Criteria for Markedly Abnormal Values

9.1.1 Hematology, Serum Chemistry, Vital Signs, and 12-lead ECG (except Upper MAV Criteria of QTcF Interval)

9.1.2 12-lead ECG (Upper MAV Criteria of QTcF Interval)

LIST OF IN-TEXT TABLES

Table 4.a Summary of Dose Cohorts

Table 4.b Schematic of Dosing and PK Sampling, by Cohort

LIST OF IN-TEXT FIGURES

Figure 4.a Schematic of Study Design
3.0 LIST OF ABBREVIATIONS

AE  adverse event
\(\text{Ae}_t\)  amount of drug excreted in urine from time 0 to time \(t\)
\(\text{Ae}_\tau\)  amount of drug excreted in urine during a dosing interval
aPTT  activated partial thromboplastin time
\(\text{AUC}_{\infty}\)  area under the plasma concentration-time curve from time 0 to infinity
\(\text{AUC}_\tau\)  area under the plasma concentration-time curve during a dosing interval
\(\text{AUC}_{\tau,\text{ss}}\)  area under the plasma concentration-time curve during a dosing interval, at steady state
BID  twice daily
BMI  body mass index
CFDA  China Food and Drug Administration
CL\(_R\)  renal clearance
\(\text{C}_{\text{max}}\)  maximum observed plasma concentration
\(\text{C}_{\text{max,ss}}\)  maximum observed plasma concentration, at steady state
CRF  case report form
CV  coefficient of variation
CYP  cytochrome P450
ECG  electrocardiogram
\(f_{e,t}\)  Fraction of administered dose of drug excreted in urine from time 0 to time \(t\). Molecular weight adjustment needed for metabolites
\(f_{e,\tau}\)  Fraction of administered dose of drug excreted in urine during a dosing interval. Molecular weight adjustment needed for metabolites.
GGT  \(\gamma\)-glutamyl transferase
HDL  high density lipoprotein
LDH  lactate dehydrogenase
LDL  low density lipoprotein
LLN  lower limit of normal
MAV  markedly abnormal values
MedDRA  Medical Dictionary for Regulatory Activities
PD  pharmacodynamics
PK  pharmacokinetics
PT  Preferred Term
PT  prothrombin time
PT/INR  prothrombin time/international normalized ratio
PTE  pretreatment event
QD  once daily
QtC\(_F\)  QT interval corrected by Fridericia’s method
SAP  statistical analysis plan
SOC  System Organ Class
TAK-438F  freebase of TAK-438
TEAE  treatment-emergent adverse event
$t_{1/2z}$  terminal disposition phase half-life
$t_{\text{max}}$  time of first occurrence of $C_{\text{max}}$
$t_{\text{max,ss}}$  time of first occurrence of $C_{\text{max}}$, at steady state
ULN  upper limit of normal
WHO Drug  World Health Organization Drug Dictionary
4.0 OBJECTIVES

4.1 Primary Objectives
The primary objective is to determine the pharmacokinetics of TAK-438 in healthy adult Chinese subjects after both single and multiple dose administration.

4.2 Secondary Objectives
Not applicable.

4.3 Additional Objectives

4.4 Study Design
This is a phase 1, parallel, open-label, single- and multiple-dose study of oral TAK-438 involving 36 healthy Chinese subjects between the ages of 18 and 45, inclusive, and considered eligible based on the inclusion and exclusion entry criteria.

Screening for potential subjects will occur between 28 and 2 days prior to confinement at the phase 1 unit. Selected eligibility criteria will be reconfirmed on Day -1 (Check In) prior to assignment to the 10 mg or 20 mg once daily or 20 mg twice daily cohort, predose blood and urine sampling for pharmacokinetic (PK) measurements will also be taken. Having fasted for a minimum of 10-hours a single oral dose of TAK-438 will be administered on Day 1 followed by a pharmacokinetic sampling period of 48 hours. On Days 3 through 9, subjects will receive their assigned daily dose(s) of TAK-438 followed by another pharmacokinetic sampling period of 48 hours (for subjects on a once daily regimen), or 12 hours (for those assigned to the 20 mg twice daily regimen). The subject will be confined to the phase 1 unit from Day -1 (Check-In) through to Day 11 (Check-Out) and will be contacted by the study site for a follow-up phone call on Day 18.

Besides monitoring concomitant medications and adverse events (AE), physical examination, electrocardiogram (ECG), vital signs and clinical laboratory tests will be conducted to monitor safety. A schematic of the study design is presented in Figure 4.a.
A summary of the dose cohorts is presented in Table 4.a.

Table 4.a  Summary of Dose Cohorts

<table>
<thead>
<tr>
<th>Cohort</th>
<th>TAK-438 Dose (shown as free base amount)</th>
<th>Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TAK-438 10 mg once daily</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>TAK-438 20 mg once daily</td>
<td>12</td>
</tr>
<tr>
<td>3</td>
<td>TAK-438 20 mg twice daily</td>
<td>12</td>
</tr>
</tbody>
</table>

A schematic of the dosing schedule and sampling, by cohort, is provided in Table 4.b.

Table 4.b  Schematic of Dosing and PK Sampling, by Cohort
5.0 ANALYSIS ENDPOINTS

5.1 Primary Endpoints

The Primary endpoints for this study are the pharmacokinetic parameters derived from the plasma and urine concentrations of TAK-438F and its metabolites M-I, M-II, M-III and M-IV-Sul assessed after the first dose on Day 1 and after the final repeat dose on Day 9 as required.

The following pharmacokinetic parameters will be calculated from plasma concentrations of TAK-438F, M-I, M-II, M-III and M-IV-Sul:

Day 1
- Maximum observed plasma concentration (C_{max}).
- Time to reach C_{max} (t_{max}).
- Area under the plasma concentration-time curve from time 0 to infinity (AUC_{∞}).
- Area under the plasma concentration-time curve during a dosing interval (AUC_{τ}).
- Terminal disposition half-life (t_{1/2z}).

Day 9
- Maximum observed plasma concentration, at steady state (C_{max,ss}).
- Time to reach C_{max} at steady state (t_{max,ss}).
- Area under the plasma concentration-time curve during a dosing interval, at steady state (AUC_{τ,ss}).

The following pharmacokinetic parameters will be calculated from urine concentrations of TAK-438F, M-I, M-II, M-III and M-IV-Sul:

Day 1
- Amount of drug excreted in urine from time 0 to time t (A_{e,t}).
- Fraction of administered dose of drug excreted in urine from time 0 to time t (f_{e,t}).
- Renal clearance (CL_{R}).

Day 9
- Amount of drug excreted in urine during a dosing interval (A_{e,τ}).
- Fraction of administered dose of drug excreted in urine during a dosing interval (f_{e,τ}).
- Renal clearance (CL_{R}).
5.2 Additional Endpoints
6.0 DETERMINATION OF SAMPLE SIZE

The sample size of 12 subjects per cohort is sufficient to evaluate the PK profile after single- and multiple-dose administration of TAK-438 10 mg and 20 mg. The sample size chosen for this study is based on precedent set by other pharmacokinetic studies of similar nature and guidelines issued by the China Food and Drug Administration (CFDA); it was not based on statistical considerations of power and sample size of TAK-438. The sample size is considered though to be sufficient for investigating the objectives of the study.
7.0 METHODS OF ANALYSIS AND PRESENTATION

7.1 General Principles

7.1.1 Study Definitions

The following definitions and calculation formulas will be used.

- **TEAE**: An AE whose date of onset occurs on or after the start of study drug. A TEAE whose relationship to study drug is missing will be considered drug-related. A TEAE whose intensity is missing will be considered severe.

- **PTE**: An AE whose date of onset occurs before the start of study drug.

- **Significant TEAE**: Any AEs (not including serious TEAEs) that led to an intervention, including withdrawal of drug treatment or significant additional concomitant therapy.

- **Descriptive statistics**: number of subjects with non-missing values, mean, standard deviation, maximum, minimum, and quartiles

- **Duration of exposure to study medication (days)**: date of last dose of study medication - date of first dose of study medication + 1

- **QTcF interval (msec)**: \( \frac{\text{QT interval (msec)}}{\text{RR interval (msec)/1000}}^{0.33} \) (rounded to the nearest whole number)

- **Baseline values**: The last evaluable observation (ie, non-missing) before the first dose of study medication. If no evaluable observation is obtained before the first dose, the baseline value will be missing.

7.1.2 Definition of Study Days

Study Day: The day before the first dose of the study medication will be defined as Study Day -1 and the day of the first dose will be defined as Study Day 1. Other study days are defined relative to Study Day 1, eg, the day 2 days prior to Study Day 1 is Day -2 and the day after Study Day 1 is Day 2.

7.1.3 Definition of Study Visit Windows

7.1.3.1 Plasma Concentrations of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul

For each time, all evaluable observation (ie, non-missing) obtained in the corresponding time interval will be used. If more than one observation lies within the same time window, the observation with the closest sampling time to the scheduled time will be used. If there are two observations equidistant to the scheduled time, the later observation will be used.
Visit: Days 1 and 9

<table>
<thead>
<tr>
<th>Visit</th>
<th>Time</th>
<th>Scheduled Time (min)</th>
<th>Time Interval (min)</th>
<th>Sampling Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days 1 and 9</td>
<td>Pre–morning dose</td>
<td>0</td>
<td>-30 – 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.25 hours post–morning dose</td>
<td>15</td>
<td>10 – 20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.5 hours post–morning dose</td>
<td>30</td>
<td>25 – 35</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.75 hours post–morning dose</td>
<td>45</td>
<td>40 – 50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 hour post–morning dose</td>
<td>60</td>
<td>55 – 65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.5 hours post–morning dose</td>
<td>90</td>
<td>85 – 95</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 hours post–morning dose</td>
<td>120</td>
<td>115 – 125</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 hours post–morning dose</td>
<td>180</td>
<td>175 – 185</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 hours post–morning dose</td>
<td>240</td>
<td>235 – 245</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 hours post–morning dose</td>
<td>360</td>
<td>355 – 365</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 hours post–morning dose</td>
<td>480</td>
<td>470 – 490</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 hours post–morning dose</td>
<td>600</td>
<td>590 – 610</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 hours post–morning dose</td>
<td>720</td>
<td>710 – 730</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16 hours post–morning dose*</td>
<td>960</td>
<td>950 – 970</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 hours post–morning dose*</td>
<td>1440</td>
<td>1430 – 1450</td>
<td></td>
</tr>
<tr>
<td></td>
<td>36 hours post–morning dose*</td>
<td>2160</td>
<td>2150 – 2170</td>
<td></td>
</tr>
<tr>
<td></td>
<td>48 hours post–morning dose*</td>
<td>2880</td>
<td>2870 – 2890</td>
<td></td>
</tr>
</tbody>
</table>

* Blood samples collection at these time points on Day 9 is not scheduled for Cohort 3, ie, subjects assigned to the 20 mg BID regimen.

Visit: Days 4-8

<table>
<thead>
<tr>
<th>Visit</th>
<th>Time</th>
<th>Scheduled Time (min)</th>
<th>Time Interval (min)</th>
<th>Sampling Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days 4 - 8</td>
<td>Pre–morning dose</td>
<td>0</td>
<td>-30 – 0</td>
<td></td>
</tr>
</tbody>
</table>

7.1.3.2 Other Endpoints

The baseline visit is defined as the period before the first dose of study medication, and post-baseline visits are defined in line with CRF-recorded visits. The last evaluable observation (ie, non-missing) in the baseline visit will be used as the baseline value, and all evaluable observation will be used for each post-baseline visit.

7.1.4 Method of Data Conversion and Handling of Missing Data

No imputation of missing data or of excluded data will be applied. Values below the lower limit of quantification will be handled as 0.
7.2 Analysis Sets

The safety analysis set used for primary analysis will consist of subjects who received at least 1 dose of the study drug.

The PK analysis set will consist of subjects who received the study drug, who have sufficient plasma/urine concentration data to calculate at least 1 pharmacokinetic parameter, and completed the minimum protocol specified procedures with no significant protocol deviations, which are listed below:

- Subjects who did not meet inclusion criteria #3, #4 or #5.
- Subjects who met exclusion criteria #1, #4, #6, #7, #10, #11, #12, #13, #14, or #18.
- Subjects who have violated the rules specified in section 7.3 (excluded medications and dietary products) of the protocol up to 48 hours after the last dose on Day 9.
- Subjects who did not receive the study drug at some scheduled time of administration.

7.3 Disposition of Subjects

7.3.1 Study Information

Analysis Set: All Subjects Who Signed the Informed Consent Form

Analysis Variables:
- Date First Subject Signed Informed Consent Form
- Date of Last Subject’s Last Visit/Contact
- MedDRA Version
- WHO Drug Version
- SAS Version Used for Creating the Datasets

Analytical Methods: (1) Study Information

Study information shown in the analysis variables section will be provided.

7.3.2 Screen Failures

Analysis Set: All Subjects Who Did Not Enter the Treatment Period

Analysis Variables:
- Age (years) \([\text{Min}<= - <30, 30<= - <40, 40<= - <=\text{Max}]\)
- Gender \([\text{Male, Female}]\)
- Race \([\text{American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White}]\)

Analytical Methods: (1) Screen Failures

Frequency distributions for categorical variables and descriptive statistics for continuous variables will be provided.
7.3.3 Subject Eligibility

Analysis Set: All Subjects Who Signed the Informed Consent Form
Analysis Variables: Eligibility Status [Yes, No]
Primary Reason for Subject Not Being Eligible [Pretreatment Event/Adverse Event, Significant Protocol Deviation, Lost to Follow-Up, Voluntary Withdrawal, Study Termination, Did Not Meet Entrance Criteria, Other]

Analytical Methods: (1) Eligibility for Entrance into the Treatment Period
Frequency distributions will be provided. When calculating the percentages for the primary reasons for subject not being eligible, the total number of ineligible subjects will be used as the denominator.

7.3.4 Disposition of Subjects

Analysis Set: All Subjects Who Entered the Treatment Period
Analysis Variables: Study Drug Administration Status [No]
Reason for Not Being Treated [Pretreatment Event/Adverse Event, Significant Protocol Deviation, Lost to Follow-Up, Voluntary Withdrawal, Study Termination, Pregnancy, Other]
Study Drug Completion Status [Completed Study Drug, Prematurely Discontinued Study Drug]
Reason for Discontinuation of Study Drug [Pretreatment Event/Adverse Event, Significant Protocol Deviation, Lost to Follow-Up, Voluntary Withdrawal, Study Termination, Pregnancy, Other]

Analytical Methods: (1) Disposition of Subjects
Frequency distributions will be provided for each cohort and overall. When calculating percentages for the reasons for not being treated, the total number of subjects not treated by the study drug will be used as the denominator. When calculating percentages for the reasons for discontinuation of study drug, the total number of subjects who prematurely discontinued the study drug will be used as the denominator.
(2) Flow Chart of Subject Distribution
Flow chart will be provided.
7.3.5 Protocol Deviations and Analysis Sets

Protocol Deviations

Analysis Set: All Subjects Who Entered the Treatment Period
Analysis Variables: Protocol Deviation [Entry Criteria, Concomitant Medication, Procedure Not Performed Per Protocol, Study Medication, Withdrawal Criteria]

Analytical Methods: (1) Protocol Deviations
Frequency distribution will be provided by cohort and overall for each deviation category. A subject who has several deviations will be counted once in each appropriate category. A subject who has several deviations that can be classified into the same category will be counted only once.

Analysis Sets

Analysis Set: All Subjects Who Entered the Treatment Period
Analysis Variables: Analysis Sets
PK Analysis Set [Included]
Safety Analysis Set [Included]

Analytical Methods: (1) Analysis Sets
Frequency distributions will be provided by cohort and overall.
7.4 Demographic and Other Baseline Characteristics

Analysis Set: PK Analysis Set  
Safety Analysis Set

Analysis Variables:
- Age (years)  
  [Min<= - <30, 30<= - <40, 40<= - <=Max]
- Gender  
  [Male, Female]
- Race  
  [American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White]
- Height (cm)  
  [Min<= - <150, 150<= - <160, 160<= - <170, 170<= - <=Max]
- Weight (kg) (Baseline)  
  [Min<= - <50.0, 50.0<= - <60.0, 60.0<= - <70.0, 70.0<= - <80.0, 80.0<= - <=Max]
- BMI (kg/m\(^2\)) (Baseline)  
  [Min<= - <19.0, 19.0<= - <=24.0, 24.0<= - <=Max]
- Smoking Classification  
  [The Subject Has Never Smoked, The Subject Is a Current Smoker, The Subject Is an Ex-smoker]
- Consumption of Alcohol  
  [Drink Every day, Drink a Couple of Days Per Week, Drink a Couple of Days Per Month, Never Drink]
- Consumption of Caffeine  
  [Yes, No]
- CYP2C19 Genotype  
  [*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3]

Analytical Methods:

1) Summary of Demographics and Other Baseline Characteristics  
Frequency distributions for categorical variables and descriptive statistics for continuous variables will be provided by cohort and overall.

7.5 Medical History and Concurrent Medical Conditions

Medical history is defined as significant conditions or diseases that stopped at or prior to the time of informed consent. Concurrent medical conditions are defined as significant conditions ongoing or present at the time of informed consent.

Medical history and concurrent medical conditions will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, version 19.0) coding system.

There will be no analysis of medical history and concurrent medical conditions.

7.6 Medication History and Concomitant Medications

Medication history information includes any medication relevant to eligibility criteria stopped prior to signing of informed consent. Concomitant medications are recorded on the eCRF and include any medications, other than the study drug, taken at any time between informed consent and on or prior to the last dose of study drug.
Medication history and concomitant medications will be coded using the World Health Organization Drug Dictionary (WHO Drug) version 2016Q1 or higher.

There will be no analysis of medication history and concomitant medications.

7.7 Efficacy Analysis
Not applicable.

7.8 Pharmacokinetic/Pharmacodynamic Analysis

7.8.1 Pharmacokinetic Analysis

Plasma Concentrations of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul

<table>
<thead>
<tr>
<th>Analysis Set:</th>
<th>PK Analysis Set</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analysis Variable:</td>
<td>Plasma Concentrations of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul</td>
</tr>
<tr>
<td>Time Point:</td>
<td>Visit: Days 1 and 9 Pre–morning dose (0 hours) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16*, 24*, 36*, 48* hours post–morning dose (relative to start time of morning dose at Day 1 or 9) * Blood samples collection at these time points on Day 9 is not scheduled for Cohort 3, ie, subjects assigned to the 20 mg BID regimen. Visit: Days 4-8 Pre–morning dose (0 hours)</td>
</tr>
<tr>
<td>Analytical Methods:</td>
<td>The following summaries will be provided for each analyte by cohort.</td>
</tr>
</tbody>
</table>

(1) Summary of Plasma Concentrations by Time Point
Descriptive statistics for observed values will be provided for each time point. In addition, geometric mean, and %CV will be provided

(2) Concentration-time Profiles for Individual Subjects
Observed values will be plotted using individual case plot.

(3) Mean Concentration-time Profiles with Standard Deviations
Mean of plasma concentration will be plotted by time point using linear scales and common log scales for Days 1-9, Day 1 and Day 9 respectively.
Plasma PK Parameters of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul

Analysis Set: PK Analysis Set
Analysis Visit and Variable: Plasma PK Parameters of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul
Visit: Day 1
- $C_{\text{max}}$
- $t_{\text{max}}$
- $AUC_\infty$
- $AUC_\tau$
- $t_{1/2z}$
- $\lambda_z$
- $CL/F$
- $V_z/F$
Visit: Day 9
- $C_{\text{max,ss}}$
- $t_{\text{max,ss}}$
- $AUC_{\tau,ss}$
- $t_{1/2z}$
- $\lambda_z$
- $CL/F_{ss}$
- $V_z/F_{ss}$
- $R_{\text{act(AUC)}}$
- $R_{\text{act(Cmax)}}$

Analytical Methods: The following summaries will be provided for each analyte by cohort.

(1) Summary of Plasma PK Parameters
Descriptive statistics for PK parameters will be provided. In addition, geometric mean and %CV will be computed for $C_{\text{max}}$ and AUCs.

Urine PK Parameters of TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul

Analysis Set: PK Analysis Set
Visit: Day 1
- $\text{Ae}_t$
- $f_{e,t}$
- $CL_R$
Visit: Day 9
- $\text{Ae}_t$
- $f_{e,\tau}$
- $CL_R$

Analytical Methods: The following summaries will be provided for each analyte by cohort.

(1) Summary of Urine PK Parameters
Descriptive statistics for PK parameters will be provided. Here, only $f_e$ will be summarized for the total of TAK-438F and its metabolites.

7.8.2 Pharmacodynamic Analysis
Not applicable.

7.9 Other Outcomes
Not applicable.
7.10  Safety Analysis

7.10.1  Adverse Events

7.10.1.1  Overview of Treatment-Emergent Adverse Events

Analysis Set: Safety Analysis Set
Analysis Variables: TEAE
Categories: Relationship to Study Drug [Related, Not Related]  
Intensity [Mild, Moderate, Severe]
Analytical Methods: The following summaries will be provided for each cohort.

(1) Overview of Treatment-Emergent Adverse Events
1) All Treatment-Emergent Adverse Events (number of events, number and percentage of subjects)
2) Relationship of Treatment-Emergent Adverse Events to Study Drug (number of events, number and percentage of subjects)
3) Intensity of Treatment-Emergent Adverse Events (number of events, number and percentage of subjects)
4) Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation (number of events, number and percentage of subjects)
5) Relationship to Study Drug of Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation (number of events, number and percentage of subjects)
6) Serious Treatment-Emergent Adverse Events (number of events, number and percentage of subjects)
7) Relationship of Serious Treatment-Emergent Adverse Events to Study Drug (number of events, number and percentage of subjects)
8) Serious Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation (number of events, number and percentage of subjects)
9) Treatment-Emergent Adverse Events Resulting in Death (number of events, number and percentage of subjects)
10) Significant Treatment-Emergent Adverse Events (number of events, number and percentage of subjects)
11) Relationship of Significant Treatment-Emergent Adverse Events to Study Drug (number of events, number and percentage of subjects)

TEAEs will be counted according to the rules below.

Number of subjects
• Summaries for 2), 5), 7) and 11)
A subject with occurrences of TEAE in both categories (ie, Related and Not Related) will be counted once in the Related category.
• Summary for 3)
A subject with multiple occurrences of TEAE will be counted once for the TEAE with the maximum intensity.
• Summaries other than 2), 3), 5), 7) and 11)
A subject with multiple occurrences of TEAE will be counted only once.

Number of events
For each summary, the total number of events will be calculated.
7.10.1.2 Displays of Treatment-Emergent Adverse Events

Analysis Set: Safety Analysis Set
Analysis Variables: TEAE
Categories: Intensity [Mild, Moderate, Severe]
Analytical Methods: The following summaries will be provided using frequency distribution for each cohort. TEAEs will be coded using the MedDRA and will be summarized using SOC and PT. SOC will be sorted alphabetically and PT will be sorted in decreasing frequency for tables provided by SOC and PT. SOC and PT will be sorted in decreasing frequency for tables provided by SOC only or PT only.

(1) Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(2) Treatment-Emergent Adverse Events by System Organ Class
(3) Treatment-Emergent Adverse Events by Preferred Term
(4) Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(5) Intensity of Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(6) Intensity of Drug-Related Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term
(7) Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System Organ Class and Preferred Term
(8) Drug-Related Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System Organ Class and Preferred Term
(9) Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(10) Serious Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(11) Significant Treatment-Emergent Adverse Events by System Organ Class and Preferred Term
(12) Drug-Related Significant Treatment-Emergent Adverse Events by System Organ Class and Preferred Term

The frequency distribution will be provided according to the rules below.

Number of subjects

- Summary tables other than (5), and (6)
  A subject with multiple occurrences of TEAE within a SOC will be counted only once in that SOC. A subject with multiple occurrences of TEAE within a PT will be counted only once in that PT. Percentages will be based on the number of subjects in the safety analysis set.

- Summary tables for (5) and (6)
  A subject with multiple occurrences of TEAE within a SOC or a PT will be counted only once for the TEAE with the maximum intensity. Percentages will be based on the number of subjects in the safety analysis set.
7.10.1.3 Displays of Pretreatment Events

Analysis Set: All Subjects Who Signed the Informed Consent Form
Analysis Variables: PTE
Analytical Methods: The following summaries will be provided using frequency distribution. PTEs will be coded using the MedDRA and will be summarized using SOC and PT. SOC will be sorted alphabetically and PT will be sorted in decreasing frequency.

(1) Pretreatment Events by System Organ Class and Preferred Term
(2) Serious Pretreatment Events by System Organ Class and Preferred Term
The frequency distribution will be provided according to the rules below.

Number of subjects
A subject with multiple occurrences of PTE within a SOC will be counted only once in that SOC. A subject with multiple occurrences of PTE within a PT will be counted only once in that PT.

7.10.2 Clinical Laboratory Evaluations

Hematology and Serum Chemistry

Analysis Set: Safety Analysis Set
Analysis Variables: Hematology

| Red blood cells (×10^{12}/L) | White blood cells (×10^{9}/L) | Hemoglobin (g/L) |
| Hematocrit (%) | Platelets (×10^{9}/L) |
| White blood cell differential (Neutrophils (%), Eosinophils (%), Basophils (%), Monocytes (%), Lymphocytes (%)) |
| PT/INR | PT (sec) | aPTT (sec) |
| Reticulocyte percentage (%) |

Serum Chemistry

| Alanine aminotransferase (U/L) | Alkaline phosphatase (U/L) | Aspartate aminotransferase (U/L) |
| GGT (U/L) | Total bilirubin (μmol/L) | Direct bilirubin (μmol/L) |
| Lactate dehydrogenase (U/L) | Creatine kinase (U/L) | Albumin (g/L) |
| Total protein (g/L) | Serum creatinine (μmol/L) | Blood urea (mmol/L) |
| Uric Acid (mmol/L) | HDL Cholesterol (mmol/L) | LDL Cholesterol (mmol/L) |
| Triglycerides (mmol/L) | Glucose (mmol/L) | Potassium (mmol/L) |
| Sodium (mmol/L) | Magnesium (mmol/L) | Calcium (mmol/L) |
| Chloride (mmol/L) | Amylase (U/L) |

Visit: Baseline, Days 3, 9 and 11.

Analytical Methods: The following summaries will be provided for each cohort. Liver function testing measurements at local laboratories are not used for the summaries.
(1) Summary of Laboratory Test Results and Change from Baseline by Visit
Descriptive statistics for observed values and changes from baseline (each post-baseline visit - baseline) will be provided for each visit.

(2) Summary of Shifts of Laboratory Test Results
Shift tables showing the number of subjects in each category at baseline and each post-baseline visit will be provided. For each laboratory test, the laboratory values will be classified as “Low”, “Normal” or “High” relative to the normal reference range provided by the central laboratory. The shift tables will be based on these classifications.

(3) Number and Percentage of Subjects with Markedly Abnormal Values of Laboratory Test results
Overall frequency distributions of MAV during treatment phase will be provided. If a laboratory test result has both lower and upper MAV criteria, analysis will be performed for each. Further details are given in Appendix.

Urinalysis
Analysis Set: Safety Analysis Set
Analysis Variables: pH
Specific gravity
Protein
Glucose
Nitrites
Bilirubin
Ketones
Urobiilogen
Microscopic Analysis
RBC (/HPF)
WBC (/HPF)
Hyaline casts (/LPF)
Granular casts (/LPF)
Epithelial cells (×10^6/L)

Visit: Baseline, Days 3, 9 and 11.
Analytical Methods: The following summaries will be provided for each cohort.

(1) Summary of Shifts of Urine Laboratory Test Results
Shift tables showing the number of subjects in each category at baseline and each post-baseline visit will be provided.
7.10.3 Vital Signs
Analysis Set: Safety Analysis Set
Analysis Variables: Body Temperature (°C)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Respiratory Rate (bpm)
Pulse (bpm)
Visit: Baseline, Days 2-11
Analytical Methods: For each variable, following summary will be provided by cohort.

(1) Summary of Vital Signs Parameters and Change from Baseline by Visit
Descriptive statistics for observed values and changes from baseline (each post-baseline visit – baseline) will be provided for each visit.

(2) Number and Percentage of Subjects with Markedly Abnormal Values of Vital Signs Parameters
Overall frequency distributions of MAV during treatment phase will be provided. If a vital sign parameter has both lower and upper MAV criteria, analysis will be performed for each. Further details are given in Appendix.

7.10.4 12-Lead ECGs
Analysis Set: Safety Analysis Set
Analysis Variables: Heart Rate (bpm)
RR Interval (msec)
PR Interval (msec)
QT Interval (msec)
QTCf Interval (msec)
QRS Interval (msec)
12-Lead ECG Interpretation
[“Within Normal Limits”,
“Abnormal, Not Clinically Significant”,
“Abnormal, Clinically Significant”]
Visit: Baseline, Days 1-11
Analytical Methods: For each variable other than 12-lead ECG interpretations, summary (1) will be provided by cohort. For 12-lead ECG interpretations, summary (3) will be provided by cohort.

(1) Summary of ECG Parameters and Change from Baseline by Visit
Descriptive statistics for observed values and changes from baseline (each post-baseline visit – baseline) will be provided for each visit.

(2) Number and Percentage of Subjects with Markedly Abnormal Values of ECG Parameters
Overall frequency distributions of MAV during treatment phase will be provided. If an ECG parameter has both lower and upper MAV criteria, analysis will be performed for each. Further details are given in Appendix.

(3) Summary of Shifts of ECG Parameters
Shift tables showing the number of subjects in each category at baseline and each post-baseline visit will be provided.

7.10.5 Other Observations Related to Safety
Not applicable.

7.11 Interim Analysis
Not applicable.

7.12 Changes in the Statistical Analysis Plan
From the SAP version 1.0, the following parts were updated. In 7.3.4, the subject flow chart was mentioned clearly. In 7.8.1, common log scales were applied to semi-log graphs for mean concentration-time profiles instead of natural log scales, and Ae was removed from the summary table for the total of TAK-438F and its metabolites. In 7.10.1.1 and 7.10.1.2, several tables for drug-related TEAEs were added. In 7.10.2, PT and microscopic analysis parameters were added to the analysis variables. In 9.1.1, the MAV criteria of blood urea was removed.
8.0 REFERENCES

Not applicable.
9.0 APPENDIX

9.1 Criteria for Markedly Abnormal Values

9.1.1 Hematology, Serum Chemistry, Vital Signs, and 12-lead ECG (except Upper MAV Criteria of QTcF Interval)

For each parameter, all evaluable data (ie, non-missing data) obtained up to Day 11 will be classified as a MAV or not. The criteria in the table below will be used.

For each parameter and subject, classifications will be made according to the conditions i) to iii) provided below. The lower and the upper criteria will be considered separately.

i) A subject with at least one evaluable data after baseline that meets the MAV criteria will be classified as a subject with MAV.

ii) A subject who does not meet condition i) and has at least one evaluable data after baseline that doesn’t meet the MAV criteria will be considered as a subject without MAV.

iii) A subject who does not meet conditions i) or ii) will be excluded from the analysis of MAV for that parameter.

### Hematology

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MAV Criteria</th>
<th>Lower Criteria</th>
<th>Upper Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red blood cells (×10^{12}/L)</td>
<td></td>
<td>&lt;0.8×LLN</td>
<td>&gt;1.2×ULN</td>
</tr>
<tr>
<td>White blood cells (×10^{9}/L)</td>
<td></td>
<td>&lt;0.5×LLN</td>
<td>&gt;1.5×ULN</td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td></td>
<td>&lt;0.8×LLN</td>
<td>&gt;1.2×ULN</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td></td>
<td>&lt;0.8×LLN</td>
<td>&gt;1.2×ULN</td>
</tr>
<tr>
<td>Platelets (×10^{9}/L)</td>
<td></td>
<td>&lt;75</td>
<td>&gt;600</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td></td>
<td>&lt;0.5×LLN</td>
<td>&gt;1.5×ULN</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td></td>
<td>-</td>
<td>&gt;2×ULN</td>
</tr>
<tr>
<td>Basophils (%)</td>
<td></td>
<td>-</td>
<td>&gt;3×ULN</td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td></td>
<td>-</td>
<td>&gt;2×ULN</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td></td>
<td>&lt;0.5×LLN</td>
<td>&gt;1.5×ULN</td>
</tr>
<tr>
<td>aPTT (sec)</td>
<td></td>
<td>&gt;1.5</td>
<td></td>
</tr>
<tr>
<td>PT/INR</td>
<td></td>
<td>&gt;1.5</td>
<td></td>
</tr>
</tbody>
</table>
### Serum Chemistry

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MAV Criteria</th>
<th>Lower Criteria</th>
<th>Upper Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine aminotransferase (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;3×ULN</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;3×ULN</td>
</tr>
<tr>
<td>Aspartate aminotransferase (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;3×ULN</td>
</tr>
<tr>
<td>GGT (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;3×ULN</td>
</tr>
<tr>
<td>Total bilirubin (μmol/L)</td>
<td>-</td>
<td></td>
<td>&gt;34.2</td>
</tr>
<tr>
<td>Direct bilirubin (μmol/L)</td>
<td>-</td>
<td></td>
<td>&gt;2×ULN</td>
</tr>
<tr>
<td>Creatine kinase (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;5×ULN</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>&lt;25</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Total protein (g/L)</td>
<td>&lt;0.8×LLN</td>
<td></td>
<td>1.2×ULN</td>
</tr>
<tr>
<td>Uric Acid (mmol/L)</td>
<td>-</td>
<td></td>
<td>&gt;0.773</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>-</td>
<td></td>
<td>&gt;2.5×ULN</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>&lt;2.8</td>
<td></td>
<td>&gt;19.4</td>
</tr>
<tr>
<td>Potassium (mmol/L)</td>
<td>&lt;3.0</td>
<td></td>
<td>&gt;6.0</td>
</tr>
<tr>
<td>Sodium (mmol/L)</td>
<td>&lt;130</td>
<td></td>
<td>&gt;150</td>
</tr>
<tr>
<td>Magnesium (mmol/L)</td>
<td>&lt;0.5</td>
<td></td>
<td>&gt;1.2</td>
</tr>
<tr>
<td>Calcium (mmol/L)</td>
<td>&lt;1.75</td>
<td></td>
<td>&gt;2.88</td>
</tr>
<tr>
<td>Chloride (mmol/L)</td>
<td>&lt;75</td>
<td></td>
<td>&gt;126</td>
</tr>
<tr>
<td>Amylase (U/L)</td>
<td>-</td>
<td></td>
<td>&gt;2×ULN</td>
</tr>
<tr>
<td>Serum creatinine (μmol/L)</td>
<td>-</td>
<td></td>
<td>&gt;177</td>
</tr>
</tbody>
</table>

### Vital Signs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MAV Criteria</th>
<th>Lower Criteria</th>
<th>Upper Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Temperature (°C)</td>
<td>&lt;35.6</td>
<td></td>
<td>&gt;37.7</td>
</tr>
<tr>
<td>Systolic Blood Pressure (mmHg)</td>
<td>&lt;85</td>
<td></td>
<td>&gt;180</td>
</tr>
<tr>
<td>Diastolic Blood Pressure (mmHg)</td>
<td>&lt;50</td>
<td></td>
<td>&gt;110</td>
</tr>
<tr>
<td>Pulse (bpm)</td>
<td>&lt;50</td>
<td></td>
<td>&gt;120</td>
</tr>
</tbody>
</table>
12-lead ECG

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MAV Criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower Criteria</td>
<td>Upper Criteria</td>
</tr>
<tr>
<td>Heart Rate (bpm)</td>
<td>&lt;50</td>
<td>&gt;120</td>
</tr>
<tr>
<td>QT Interval (msec)</td>
<td>&lt;=50</td>
<td>&gt;=460</td>
</tr>
<tr>
<td>QTcF Interval (msec)</td>
<td>&lt;=50</td>
<td>-</td>
</tr>
</tbody>
</table>

9.1.2 12-lead ECG (Upper MAV Criteria of QTcF Interval)

All evaluable data (ie, non-missing data) obtained up to Day 11 will be classified as a MAV or not. The criteria in the table below will be used. Note that the observed value and the change from baseline used for classification should be measurements taken on the same day.

For each subject, classifications will be made according to the conditions i) to iii) provided below.

i) A subject with at least one evaluable data after baseline that meets the MAV criteria will be classified as a subject with MAV.

ii) A subject who does not meet condition i) and has at least one evaluable data after baseline that meets any of the following will be considered as a subject without MAV.

- Observed value is less than 450 msec and not missing.
- Change from baseline is less than 30 msec and not missing, and observed value is less than 500 msec and not missing.

iii) A subject who does not meet conditions i) or ii) will be excluded from the analysis of MAV.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MAV Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTcF Interval (msec)</td>
<td>If either of the following conditions is met:</td>
</tr>
<tr>
<td></td>
<td>observed value &gt;=500</td>
</tr>
<tr>
<td></td>
<td>change from baseline &gt;= 30 and observed value &gt;=450</td>
</tr>
</tbody>
</table>
# ELECTRONIC SIGNATURES

<table>
<thead>
<tr>
<th>Signed by</th>
<th>Meaning of Signature</th>
<th>Server Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPD</td>
<td>Biostatistics Approval</td>
<td>04-Sep-2017 01:41 UTC</td>
</tr>
<tr>
<td>PPD</td>
<td>Clinical Pharmacology Approval</td>
<td>04-Sep-2017 04:06 UTC</td>
</tr>
<tr>
<td>PPD</td>
<td>Biostatistics Approval</td>
<td>04-Sep-2017 13:13 UTC</td>
</tr>
<tr>
<td>PPD</td>
<td>Clinical Approval</td>
<td>06-Sep-2017 04:56 UTC</td>
</tr>
<tr>
<td>PPD</td>
<td>Pharmacovigilance Approval</td>
<td>19-Sep-2017 12:11 UTC</td>
</tr>
</tbody>
</table>